Soluble and cell-associated transferrin receptor in lung cancer.

por Dowlati, A., Loo, M., Bury, T., Fillet, G., Beguin, Y.
Publicado 1997

Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263

por Greenberg, E F, McColl, K S, Zhong, F, Wildey, G, Dowlati, A, Distelhorst, C W
Publicado 2015

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

por Tan, A R, Dowlati, A, Stein, M N, Jones, S F, Infante, J R, Bendell, J, Kane, M P, Levinson, K T, Suttle, A B, Burris III, H A
Publicado 2014

Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States

por Jain, P., Gutierrez Bugarin, J., Guha, A., Jain, C., Patil, N., Shen, T., Stanevich, I., Nikore, V., Margolin, K., Ernstoff, M., Velcheti, V., Barnholtz-Sloan, J., Dowlati, A.
Publicado 2021

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer

por Rudin, C.M., Cervantes, A., Dowlati, A., Besse, B., Ma, B., Costa, D.B., Schmid, P., Heist, R., Villaflor, V.M., Spahn, J., Li, S., Cha, E., Riely, G.J., Gettinger, S.
Publicado 2023

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

por Tang, Z, Du, R, Jiang, S, Wu, C, Barkauskas, D S, Richey, J, Molter, J, Lam, M, Flask, C, Gerson, S, Dowlati, A, Liu, L, Lee, Z, Halmos, B, Wang, Y, Kern, J A, Ma, P C
Publicado 2008

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

por Hong, D S, Bauer, T M, Lee, J J, Dowlati, A, Brose, M S, Farago, A F, Taylor, M, Shaw, A T, Montez, S, Meric-Bernstam, F, Smith, S, Tuch, B B, Ebata, K, Cruickshank, S, Cox, M C, Burris, H A, Doebele, R C
Publicado 2019